Roche: Franc hits first half’s earnings

Comment on this story

Roche’s first-half profit fell 7 percent as the strength of the Swiss franc offset rising sales of new medicines, the biggest maker of cancer drugs said yesterday. Net income declined to Sf5.6 billion (R65.3bn), it said. Earnings a share excluding some items, known as core earnings a share, came in at Sf7.57, above the Sf7.43 average of eight estimates. The firm’s new breast cancer drugs delivered growth. Kadcyla sales almost tripled to Sf227 million at constant exchange rates, and Perjeta sales nearly quadrupled. Roche reiterated a full-year forecast of low- to mid-single-digit revenue gains, in line with a 5 percent increase in the first half. Roche shares gained 1.2 percent to Sf269.70 by midday in Zurich. – Bloomberg

sign up

Comment Guidelines

  1. Please read our comment guidelines.
  2. Login and register, if you haven’ t already.
  3. Write your comment in the block below and click (Post As)
  4. Has a comment offended you? Hover your mouse over the comment and wait until a small triangle appears on the right-hand side. Click triangle () and select "Flag as inappropriate". Our moderators will take action if need be.

  5. Verified email addresses: All users on Independent Media news sites are now required to have a verified email address before being allowed to comment on articles. You are only required to verify your email address once to have full access to commenting on articles. For more information please read our comment guidelines